Centessa Pharmaceuticals plc — Director's Dealing 2021

Jun 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-05-27

Reporting Person: YVER ANTOINE (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-27	Ordinary Shares	A	833897	$0.00	Acquired	833897	Direct

Footnotes

F1: Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: The shares are subject to a right of repurchase by the Issuer, which vest as follows: 25% of the shares will vest on May 17, 2022 and the remaining 75% of the shares will vest in 36 monthly installments on the first day of each month thereafter.